Matches in SemOpenAlex for { <https://semopenalex.org/work/W2090874286> ?p ?o ?g. }
Showing items 1 to 73 of
73
with 100 items per page.
- W2090874286 abstract "As no standard chemotherapy regimen has been established for advanced gastric cancer, this study sought to evaluate the efficacy and safety of combination chemotherapy that included paclitaxel and leucovorin (LV)-modulated infusional 5-fluorouracil (5-FU) in metastatic gastric cancer. Patients received a three-hour infusion of 175 mg/m2 of paclitaxel on day 1. A bolus of 20 mg/m2 of LV was then administered, followed by a 24-h infusion of 1,000 mg/m2 of 5-FU on days 1 through 3. The treatment cycle was re-peated every 3 weeks until disease progression. Response evaluation was performed according to the RECIST criteria, with toxicity determined by NCI-CTC (version 2.0). A total of 66 patients, including 21 (31.8%) with a history of prior chemotherapy, were enrolled. Fifteen (71.4%) of the 21 patients with prior chemotherapy received prolonged infusional 5-FU. In the 56 evaluable patients (37 in the chemotherapy-naïve group and 19 in the prior chemotherapy group), tumor responses according to prior exposure to chemotherapy were as follows: 17 (45.9%) partial response (PR), 6 (16.2%) stable disease (SD) and 14 (37.8%) progressive disease (PD) in the chemotherapy-naïve group; 1 (7.1%) complete response, 3 (15.8%) PRs, 8 (42.1%) SDs and 7 (36.8%) PDs in the prior chemotherapy group. The overall median response duration was 20 weeks (range, 8-61 weeks), with a median progression-free survival of 20 weeks [95% confidence interval (CI), 13.4-26.6 weeks] and 12 weeks (95% CI, 5.7-18.3 weeks) in the chemotherapy-naïve and prior chemotherapy groups, respectively. The median overall survival was 48 weeks (95% CI, 38-58 weeks) in the chemotherapy-naïve group and 28 weeks (95% CI, 22-34 weeks) in the prior chemotherapy group. The most frequent grade III/IV toxicity was neutro-penia. Non-hematological toxicity of grade III/IV was rare. Paclitaxel in combination with 5-FU/LV is clinically beneficial for patients with advanced gastric cancer and is a feasible salvage regimen for 5-FU-refractory gastric cancer patients." @default.
- W2090874286 created "2016-06-24" @default.
- W2090874286 creator A5005358526 @default.
- W2090874286 creator A5006337020 @default.
- W2090874286 creator A5030577122 @default.
- W2090874286 creator A5033290351 @default.
- W2090874286 creator A5064697305 @default.
- W2090874286 creator A5071819927 @default.
- W2090874286 creator A5085725295 @default.
- W2090874286 date "2006-03-01" @default.
- W2090874286 modified "2023-09-27" @default.
- W2090874286 title "Paclitaxel and leucovorin-modulated infusional 5-fluorouracil combination chemotherapy for metastatic gastric cancer" @default.
- W2090874286 doi "https://doi.org/10.3892/or.15.3.621" @default.
- W2090874286 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/16465422" @default.
- W2090874286 hasPublicationYear "2006" @default.
- W2090874286 type Work @default.
- W2090874286 sameAs 2090874286 @default.
- W2090874286 citedByCount "3" @default.
- W2090874286 countsByYear W20908742862012 @default.
- W2090874286 countsByYear W20908742862020 @default.
- W2090874286 crossrefType "journal-article" @default.
- W2090874286 hasAuthorship W2090874286A5005358526 @default.
- W2090874286 hasAuthorship W2090874286A5006337020 @default.
- W2090874286 hasAuthorship W2090874286A5030577122 @default.
- W2090874286 hasAuthorship W2090874286A5033290351 @default.
- W2090874286 hasAuthorship W2090874286A5064697305 @default.
- W2090874286 hasAuthorship W2090874286A5071819927 @default.
- W2090874286 hasAuthorship W2090874286A5085725295 @default.
- W2090874286 hasBestOaLocation W20908742861 @default.
- W2090874286 hasConcept C121608353 @default.
- W2090874286 hasConcept C126322002 @default.
- W2090874286 hasConcept C141071460 @default.
- W2090874286 hasConcept C143998085 @default.
- W2090874286 hasConcept C2776694085 @default.
- W2090874286 hasConcept C2777292972 @default.
- W2090874286 hasConcept C2778336483 @default.
- W2090874286 hasConcept C2778822529 @default.
- W2090874286 hasConcept C2779984678 @default.
- W2090874286 hasConcept C2780456651 @default.
- W2090874286 hasConcept C2781413609 @default.
- W2090874286 hasConcept C71924100 @default.
- W2090874286 hasConcept C90924648 @default.
- W2090874286 hasConceptScore W2090874286C121608353 @default.
- W2090874286 hasConceptScore W2090874286C126322002 @default.
- W2090874286 hasConceptScore W2090874286C141071460 @default.
- W2090874286 hasConceptScore W2090874286C143998085 @default.
- W2090874286 hasConceptScore W2090874286C2776694085 @default.
- W2090874286 hasConceptScore W2090874286C2777292972 @default.
- W2090874286 hasConceptScore W2090874286C2778336483 @default.
- W2090874286 hasConceptScore W2090874286C2778822529 @default.
- W2090874286 hasConceptScore W2090874286C2779984678 @default.
- W2090874286 hasConceptScore W2090874286C2780456651 @default.
- W2090874286 hasConceptScore W2090874286C2781413609 @default.
- W2090874286 hasConceptScore W2090874286C71924100 @default.
- W2090874286 hasConceptScore W2090874286C90924648 @default.
- W2090874286 hasLocation W20908742861 @default.
- W2090874286 hasLocation W20908742862 @default.
- W2090874286 hasOpenAccess W2090874286 @default.
- W2090874286 hasPrimaryLocation W20908742861 @default.
- W2090874286 hasRelatedWork W103651400 @default.
- W2090874286 hasRelatedWork W2046076775 @default.
- W2090874286 hasRelatedWork W2090874286 @default.
- W2090874286 hasRelatedWork W2356680716 @default.
- W2090874286 hasRelatedWork W2356841120 @default.
- W2090874286 hasRelatedWork W2363409655 @default.
- W2090874286 hasRelatedWork W2364816840 @default.
- W2090874286 hasRelatedWork W2413859356 @default.
- W2090874286 hasRelatedWork W2415089730 @default.
- W2090874286 hasRelatedWork W94772370 @default.
- W2090874286 isParatext "false" @default.
- W2090874286 isRetracted "false" @default.
- W2090874286 magId "2090874286" @default.
- W2090874286 workType "article" @default.